Grace Capital’s CytomX Therapeutics CTMX Stock Holding History

Grace Capital’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,888	Closed	-$35K	–	219
2018 Q3	$35K	Buy	+1,888	New	+$43K	0.01%	199

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Grace Capital's CTMX Position: Q4 2018 in Review

Grace Capital sold out of CytomX Therapeutics (CTMX) in Q4 2018, closing a stake of 1,888 shares — an estimated $35K sold.

Grace Capital first reported a position in CTMX in Q3 2018 and held it in 1 quarter. The position peaked at $35K in Q3 2018. 111 funds tracked by Wall St. Rank hold CTMX as of Q4 2018.

Grace Capital reported no remaining CytomX Therapeutics position as of Q4 2018 after selling out during the quarter.
Grace Capital sold 1,888 CytomX Therapeutics shares in Q4 2018, an estimated $35K.
Grace Capital first reported a position in CytomX Therapeutics in Q3 2018 and held it in 1 quarter.
Grace Capital's CytomX Therapeutics position peaked at $35K in Q3 2018.
111 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2018.

Based on Grace Capital's 13F filing for Q4 2018, filed 15 Feb 2019.